Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting

(2016) Robert S. Zeiger et al.   Journal of Allergy and Clinical Immunology-In Practice

Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting

(2016) Benjamin Chastek et al.   Journal of Managed Care & Specialty Pharmacy

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Asthma in USA: its impact on health-related quality of life

(2013) Patrick W. Sullivan et al.   JOURNAL OF ASTHMA

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma

(2012) Jasmina I. Ivanova et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

The placebo response in clinical trials: more questions than answers

(2011) P. Enck et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthma

(2010) William W. Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations

(2009) Helen K. Reddel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up study

(2009) Ilonka H. van Veen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Economic burden of asthma: a systematic review

(2009) Katayoun Bahadori et al.   BMC Pulmonary Medicine